Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2822
Source ID: NCT04513704
Associated Drug: Oral Semaglutide
Title: A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Healthy Volunteers Type 2 Diabetes
Interventions: DRUG: Oral Semaglutide
Outcome Measures: Primary: Area under the semaglutide plasma concentration - time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,day10), nmol\*h/L, From 0 to 24 hours after the 10th dosing (day 10) | Secondary: Maximum observed semaglutide plasma concentration after the 10th dosing (Cmax,0-24h,sema,day10), nmol/L, From 0 to 24 hours after the 10th dosing (day 10)|Time to maximum observed semaglutide plasma concentration after the 10th dosing (tmax,0-24h,sema,day10), hours (h), From 0 to 24 hours after the 10th dosing (day 10)
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT
Phases: PHASE1
Enrollment: 156
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2020-08-28
Completion Date: 2021-05-26
Results First Posted:
Last Update Posted: 2023-05-12
Locations: Novo Nordisk Investigational Site, Harrow, HA1 3UJ, United Kingdom
URL: https://clinicaltrials.gov/show/NCT04513704